Vera Therapeutics seeks full FDA approval for Trutakna after two-year IgAN trial success

Key points

• Vera Therapeutics announced that Trutakna (atacicept-vymj) stabilized estimated glomerular filtration rate (eGFR) and prevented disease progression in the final efficacy analysis of the ORIGIN 3 trial.
• The drug reduced the risk of kidney-related death and other complications in patients with IgA nephropathy, a chronic autoimmune condition caused by antibody buildup in the kidneys.
• The FDA granted accelerated approval to Trutakna in July 2026, and Vera intends to apply for full approval during the fourth quarter of 2026.
• IgA nephropathy leads to progressive loss of kidney function and can result in organ failure requiring dialysis, making effective treatments critical for patient outcomes.

Background

This development follows Vera Therapeutics' July 2026 accelerated approval for Trutakna. The company is now leveraging long-term trial data to transition from accelerated to full regulatory approval. This mirrors broader biotech trends where companies seek definitive efficacy data to solidify market positioning, similar to recent approvals in other therapeutic areas like rare blood cancers and autoimmune disorders.

How outlets are covering it

STAT reported the core outcome that Trutakna stabilized kidney function and reduced mortality risks, emphasizing the strategic move toward full FDA approval. Yahoo Finance highlighted the specific metric that atacicept stabilized eGFR and prevented progression, focusing on the clinical trial name ORIGIN 3. HCPLive quantified the efficacy, stating that atacicept cut the risk of IgAN progression by 76%, providing a concrete statistical measure of the drug's impact. While all sources agree on the positive results, HCPLive offers the most specific efficacy percentage, whereas STAT focuses on the regulatory timeline.

Why it matters

The success of Trutakna in the ORIGIN 3 trial provides a potential long-term treatment option for IgA nephropathy, a disease with limited therapeutic options that often leads to dialysis. Full FDA approval would solidify the drug's market position and potentially improve patient outcomes by preventing kidney failure. This milestone also demonstrates the viability of atacicept as a treatment for autoimmune kidney diseases, influencing future drug development in nephrology.

What to watch

Vera Therapeutics plans to submit an application for full FDA approval for Trutakna in the fourth quarter of 2026. The company will likely continue to monitor long-term safety and efficacy data as it transitions from accelerated to full approval. Investors and healthcare providers will watch for regulatory decisions and potential market expansion for the drug.